Aclarion Announces Closing of $3.0 Million Public Offering
BROOMFIELD, CO, Feb. 27, 2024 (GLOBE NEWSWIRE) — via NewMediaWire – Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq:ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, today announced the closing of its public offering of 5,175,000 units, with each unit consisting of one share of common stock (or one pre-funded warrant in lieu thereof), and two common warrants, with each common warrant to purchase one share of common stock. Each unit was sold at a public offering price of $0.58. The common warrants are immediately exercisable at a price of $0.58 per share and expire five years from the date of issuance. The shares of common stock (or pre-funded warrants in lieu thereof) and accompanying warrants were only purchasable together in this offering, but were issued separately and immediately separable upon issuance.